Form D · Biotechnology
Benitec Biopharma Inc.
Hayward, CA · CIK 0001808898
Offering snapshot reported Apr 25, 2024 · SEC filing
- Reported sold
- $40M Offering amount: $40M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 22, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 25, 2024 | Initial | $40,000,018 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.4M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-511623
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners LLC | 39011 | |
| Citizens JMP Securities, LLC | 22208 |
Source: Form D, filed Apr 25, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jerel Banks | Director, Executive |
| Megan Boston | Director, Executive |
| J. Kevin Buchi | Director |
| Peter Francis | Director |
| Edward Smith | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3940 Trust Way
Hayward, CA, 94545
Hayward, CA, 94545